Stryker Corporation (SYK)
Stryker Corporation (SYK) carries a ŷRobot AI score of 55 out of 100. The model's fair value estimate is $294.57, 4.9% below the last close of $309.64. The chart signal reads Hold.
| Metric | SYK |
|---|---|
| AI score | 55 / 100 |
| Chart signal | Hold |
| Fair value estimate | $294.57 |
| Upside to fair value | -4.9% |
| Previous close | $309.64 |
| P/E | 31.08 |
| Price / sales | 4.22 |
| Market cap | $118.92B |
| EPS | 9.39 |
| Revenue growth | 10.2% |
| 1-year price change | 9.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about SYK
Is SYK overvalued or undervalued right now?
As of Nov 2, 2026, ŷRobot's fair-value model estimates Stryker Corporation (SYK) at $294.57 against a last close of $309.64, implying 4.9% downside to the model's estimate.
Is SYK's chart signal bullish or bearish?
The chart-signal model classifies SYK as Neutral as of Nov 14, 2026, with a signal score of -0.06 on a -1 to 1 scale.
What is SYK's ŷRobot AI score?
SYK scores 55 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 14, 2026.
Is SYK stock expensive on P/E and P/S?
SYK trades at 31.1 times earnings and 4.2 times sales as of Nov 14, 2026.
What does SYK's seasonal forecast show?
ŷRobot's seasonal forecast curve for SYK reads +2.4% at 30 days, +8.9% at 90 days, and +9.4% at one year as of Nov 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is SYK growing?
Stryker Corporation's revenue growth is +10.2% and free-cash-flow growth is -4.9% on the latest reported figures.
SYK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.